Literature DB >> 11992585

Local treatment of HPV-induced skin lesions by Cidofovir.

Ilse Stragier1, Robert Snoeck, Erik De Clercq, Joost J Van Den Oord, Marc Van Ranst, Hugo De Greef.   

Abstract

Human papillomavirus (HPV) induced epithelial cell proliferation is responsible for a broad range of lesions. Treatment of such lesions is characterized by a high relapse rate. Four patients are described who were treated locally with cidofovir (cream 1% or injection of 2.5 mg/ml solution) for multi-treated relapsing HPV-associated lesions. Three of the four patients had a complete response. The fourth patient showed a clinical response in the first cycle of treatment, but new lesions appeared during four successive cycles of cidofovir. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11992585     DOI: 10.1002/jmv.2213

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  6 in total

1.  Topical therapies for the treatment of anal high-grade squamous intraepithelial lesions.

Authors:  Christina Megill; Timothy Wilkin
Journal:  Semin Colon Rectal Surg       Date:  2017-04-26

Review 2.  Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections.

Authors:  Erik De Clercq
Journal:  Clin Microbiol Rev       Date:  2003-10       Impact factor: 26.132

3.  Assessing the efficacy of cidofovir against herpesvirus-induced genital lesions in goats using different therapeutic regimens.

Authors:  M Tempesta; G Crescenzo; M Camero; A L Bellacicco; E Tarsitano; N Decaro; J Neyts; V Martella; C Buonavoglia
Journal:  Antimicrob Agents Chemother       Date:  2008-09-02       Impact factor: 5.191

4.  Therapeutic paint of cidofovir/sucralfate gel combination topically administered by spraying for treatment of orf virus infections.

Authors:  Fabio Sonvico; Gaia Colombo; Laura Gallina; Fabrizio Bortolotti; Alessandra Rossi; Colin J McInnes; Gina Massimo; Paolo Colombo; Alessandra Scagliarini
Journal:  AAPS J       Date:  2009-04-21       Impact factor: 4.009

5.  Formulation of cidofovir improves the anti-papillomaviral activity of topical treatments in the CRPV/rabbit model.

Authors:  Neil D Christensen; Nancy M Cladel; Jiafen Hu; Karla K Balogh
Journal:  Antiviral Res       Date:  2014-06-16       Impact factor: 5.970

6.  Reduced tumorigenicity and pathogenicity of cervical carcinoma SiHa cells selected for resistance to cidofovir.

Authors:  Tim De Schutter; Graciela Andrei; Dimitri Topalis; Sophie Duraffour; Tania Mitera; Joost van den Oord; Patrick Matthys; Robert Snoeck
Journal:  Mol Cancer       Date:  2013-12-10       Impact factor: 27.401

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.